REG - ITV PLC - ITV Announces Investment in Flarin

ITVAnnouncement

15/08/2023 14:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230815:nRSO3981Ja&default-theme=true

RNS Number : 3981J  ITV PLC  15 August 2023

ITV Announces Investment in Flarin

 

London, 15 August 2023

 

ITV today announces its third 2023 deal as part of its Media for Equity
portfolio, in pain relief brand Flarin - its first consumer healthcare
investment to date.

 

As part of ITV Adventures Invest, its Media for Equity investment fund, ITV
has agreed to subscribe for £2 million of shares in Flarin Holdings Limited,
with the option to subscribe for two additional tranches of £1.5 million
each, in return for advertising inventory across ITV's channels and ITVX. It
follows ITV's recent Media for Equity investments in architectural design
company Resi plus pet health and wellness company PitPat, both announced
earlier this year.

 

Flarin is a unique and patent protected anti-inflammatory painkiller. Its
lipid formulation has been clinically proven to be as effective as twice the
dose of standard ibuprofen in patients with acute joint pain. Flarin is one of
the fastest growing analgesics in the UK and offers consumers a targeted
solution for joint and muscular pain relief. It is the only lipid formulated
oral analgesic available in the UK.

ITV's investment will help Flarin build mass market brand awareness by
bringing the brand to millions of consumers via ITV platforms. This will be a
step change in the size of the campaign and the approach to scaling the Flarin
brand to date.

 

Director of ITV AdVentures, Sheena Amin said: "It's fantastic to be announcing
our latest Media for Equity investment into Flarin. With its innovative and
patented lipid technology, Flarin offers many unique benefits to those
suffering from joint and muscular pain compared to any other product on the
market. Flarin is already one of the fastest growing analgesics in the market
and I am confident that we will see the company grow to new heights following
a brand building campaign across ITV."

 

MD of Flarin, Philip Lindsell said: "Pain and inflammation are increasing and
global problems for an ageing world population. Many consumers are already
finding that Flarin delivers better relief from their joint and muscular pain.

 

We are delighted to welcome ITV as an investor as they will be directly
instrumental in promoting much wider awareness of the benefits of Flarin. We
know that TV is an effective means of reaching consumers, so with the wide
availability of Flarin in supermarkets and pharmacies I am confident that a
sustained and robust campaign across ITV and ITVX will help many more
consumers to use it for effective relief from their joint pain and
inflammation."

 

Flarin Holdings Ltd brings real innovation in the over-the-counter (OTC)
market, offering a unique product which has clinical data supporting its
effectiveness in treating acute inflammatory pain conditions. Flarin® is the
first and only OTC lipid-formulated ibuprofen clinically proven to relieve
flaring joint pain. Flarin's patented lipid technology is based on a complex
manufacturing process which involves heating and dissolving specific
pharmaceutical grade lipids, ibuprofen and other excipients together in a
process lasting three days. Flarin® encases ibuprofen in lipids which help it
to travel through the stomach and into the small intestine where it is
absorbed.

 

Flarin was initially launched in the UK in 2018 as a pharmacy only product,
but in 2020 distribution was expanded into grocery and other retail outlets
making Flarin Joint & Muscular Pain Relief available for consumers to
self-select. Patents for the Flarin formulation are also held in 26 other
countries.

 

Flarin Holdings Ltd was advised by Bosham Capital Advisors for the investment
by ITV AdVentures.

 

Launched in 2021, ITV AdVentures Invest is a Media for Equity programme which
sees ITV take minority stakes in early stage digital and direct-to-consumer
businesses, in return for advertising inventory across ITV's range of
market-leading channels and ITVX. The initiative represents an innovative
opportunity for consumer businesses seeking to build scale through TV
advertising, alongside a strategic media partner. In turn, ITV benefits from a
share in the financial returns of the media investment and strategic insights
related to direct-to-consumer businesses.

 

NOTES:

 

1.   The investment will be held at its fair value on ITV's balance sheet
and will not be consolidated.

2.   In the unaudited accounts of Flarin Holdings Limited for the year ended
31 December 2021, reported gross assets were £10.9m and the net loss was
£2.2m. The Company is based in London, UK and has 8 employees.

3.   This disclosure is being made in accordance with listing rule 10.4.1 as
the parties have agreed to certain customary minority rights and obligations,
including, but not limited to, drag obligations.

 

For further enquiries please contact:

 

Investor Relations

Pippa Foulds +44 7778 031097

Sarah Comfort +44 7551 798668

 

Media Relations

Paul Moore +44 7860 794444

Laura Wootton +44 7917862293

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  JVEUVUAROOUWAAR